{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:45:16Z","timestamp":1794221116806,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaut.2025.103416","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:22:07Z","timestamp":1744147327000},"page":"103416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach"],"prefix":"10.1016","volume":"153","author":[{"given":"Annalisa","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Genovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pontarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Currado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia Pia","family":"Di Corcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103416_bib1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103416_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2012.01.006","article-title":"Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects","volume":"39","author":"Tzioufas","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103416_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semarthrit.2017.11.007","article-title":"Assessing health-related quality of life in primary Sj\u00f6gren\u2019s syndrome\u2014the PSS-QoL","volume":"48","author":"Lackner","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103416_bib4","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/jcm12072586","article-title":"Interstitial lung disease and pulmonary damage in primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis","volume":"12","author":"Berardicurti","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jaut.2025.103416_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2025.103416_bib8","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2025.103416_bib9","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jaut.2025.103416_bib10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jaut.2025.103416_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2474-15-21","article-title":"The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy in patients with primary Sj\u00f6gren\u2019s Syndrome","volume":"15","author":"Brown","year":"2014","journal-title":"BMC Muscoskelet. Disord."},{"key":"10.1016\/j.jaut.2025.103416_bib12","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib13","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"Van Der Heijden","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib14","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103416_bib16","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"Clair","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2025.103416_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.41451","article-title":"Efficacy and safety of low-dose Interleukin 2 for primary sj\u00f6gren syndrome: a randomized clinical trial","volume":"5","author":"He","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jaut.2025.103416_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2025.103416_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/art.43059","article-title":"Safety and efficacy of ianalumab in patients with Sj\u00f6gren\u2019s disease: 52\u2010week results from a randomized, placebo\u2010controlled, phase 2b dose\u2010ranging study","author":"D\u00f6rner","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/annrheumdis-2024-eular.LBA90","article-title":"LBA0010 efficacy and safety of nipocalimab, an anti-fcrn monoclonal antibody, in primary sjogren\u2019s disease: results from a phase 2, multicenter, randomized, placebo-controlled, double-blind study (dahlias)","volume":"83","author":"Gottenberg","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/rheumatology\/keq047","article-title":"Articular manifestations in primary Sjogren's syndrome: clinical significance and prognosis of 188 patients","volume":"49","author":"Fauchais","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib24","first-page":"485","article-title":"Articular manifestations of primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Castro-Poltronieri","year":"1983","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/rheumatology\/32.7.609","article-title":"The arthropathy of Sj\u00f6gren\u2019s syndrome","volume":"32","author":"Pease","year":"1993","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib26","first-page":"1352","article-title":"Are there clinical or serological differences between male and female patients with primary Sj\u00f6gren\u2019s syndrome?","volume":"31","author":"D\u00edaz-L\u00f3pez","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9343(86)90044-6","article-title":"Primary Sj\u00f6gren\u2019s syndrome in men. Clinical, serologic, and immunogenetic features","volume":"80","author":"Molina","year":"1986","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jaut.2025.103416_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/096120330000900111","article-title":"Primary Sjo\u00f6gren\u2019s syndrome in men: clinical and immunological characteristics","volume":"9","author":"Cervera","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jaut.2025.103416_bib29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib30","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren\u2019s syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib32","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib34","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/annrheumdis-2021-222053","article-title":"Pilot study of baricitinib for active Sjogren's syndrome","volume":"81","author":"Bai","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study","volume":"15","author":"Carubbi","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103416_bib37","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103416_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment: Figure 1","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib39","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren\u2019s syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib40","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren\u2019s syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jaut.2025.103416_bib41","first-page":"317","article-title":"Abatacept treatment of patients with primary Sj\u00f6gren\u2019s syndrome results in a decrease of germinal centres in salivary gland tissue","volume":"35","author":"Haacke","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib43","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib44","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103416_bib45","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib47","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103416_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2025.103416_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003766","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jaut.2025.103416_bib50","first-page":"2357","article-title":"The clinical phenotype of primary Sj\u00f6gren\u2019s syndrome patients with lymphadenopathy","volume":"40","author":"Stergiou","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103416_bib52","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jaut.2025.103416_bib53","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.42772","volume":"76","author":"Pontarini","year":"2024","journal-title":"Arthritis Rheumatol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T06:23:09Z","timestamp":1746166989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":53,"alternative-id":["S0896841125000617"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103416","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103416"}}